These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1628 related articles for article (PubMed ID: 30060362)
1. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma]. Ding CY; Guo Z; Sun J; Yang WP; Li TR Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362 [No Abstract] [Full Text] [Related]
2. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma. Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082 [TBL] [Abstract][Full Text] [Related]
3. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma. Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875 [TBL] [Abstract][Full Text] [Related]
4. [Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma]. Wu LL; Liang JH; Wang L; Xu W; Ding CY Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):831-836. PubMed ID: 31770850 [No Abstract] [Full Text] [Related]
5. Evaluation of the prognostic value of different methods of calculating the tumour metabolic volume with Guzmán Ortiz S; Mucientes Rasilla J; Vargas Núñez JA; Royuela A; Navarro Matilla B; Mitjavila Casanovas M Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(6):340-346. PubMed ID: 32646783 [TBL] [Abstract][Full Text] [Related]
6. Predictive value of F-18 FDG PET/CT quantization parameters for progression-free survival in patients with diffuse large B-cell lymphoma. Xie M; Zhai W; Cheng S; Zhang H; Xie Y; He W Hematology; 2016 Mar; 21(2):99-105. PubMed ID: 26183456 [TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of Volumetric Parameters Measured by Pretreatment 18F FDG PET/CT in Patients With Cutaneous Malignant Melanoma. Son SH; Kang SM; Jeong SY; Lee SW; Lee SJ; Lee J; Ahn BC Clin Nucl Med; 2016 Jun; 41(6):e266-73. PubMed ID: 27055144 [TBL] [Abstract][Full Text] [Related]
8. Comparison of the prognostic values of Lim CH; Hyun SH; Moon SH; Cho YS; Choi JY; Lee KH Sci Rep; 2020 Jul; 10(1):12748. PubMed ID: 32728134 [TBL] [Abstract][Full Text] [Related]
9. [Prognostic Value of Su JM; Zheng QZ; Huang WR; Deng J; Wu J; Lu HQ Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1181-1186. PubMed ID: 34362500 [TBL] [Abstract][Full Text] [Related]
10. [Value of Zhang YY; Chen WY; Cui YP; Gao XR; Hu JX; Li ZZ; Hu K Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1342-1249. PubMed ID: 30295248 [TBL] [Abstract][Full Text] [Related]
11. Prognostic value of metabolic tumour volume on baseline Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463 [TBL] [Abstract][Full Text] [Related]
12. A better prediction of progression-free survival in diffuse large B-cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV Zhang YY; Song L; Zhao MX; Hu K Cancer Med; 2019 Sep; 8(11):5137-5147. PubMed ID: 31343111 [TBL] [Abstract][Full Text] [Related]
13. [ Gui J; Li M; Xu J; Zhang X; Mei H; Lan X Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2308-2319. PubMed ID: 38467921 [TBL] [Abstract][Full Text] [Related]
14. Predictive value of F-18 FDG PET/CT quantization parameters in diffuse large B cell lymphoma: a meta-analysis with 702 participants. Xie M; Wu K; Liu Y; Jiang Q; Xie Y Med Oncol; 2015 Jan; 32(1):446. PubMed ID: 25511321 [TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents. Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043 [TBL] [Abstract][Full Text] [Related]
16. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer. Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369 [TBL] [Abstract][Full Text] [Related]
17. Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment? Evangelista L; Cervino AR; Ghiotto C; Saibene T; Michieletto S; Fernando B; Orvieto E; Guarneri V; Conte P Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1648-1655. PubMed ID: 26025244 [TBL] [Abstract][Full Text] [Related]
18. [Prognostic value of (18)F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) in extensive-stage small cell lung cancer]. Ding CY; Guo Z; Li YY; Li TR Zhonghua Zhong Liu Za Zhi; 2017 Nov; 39(11):828-834. PubMed ID: 29151289 [No Abstract] [Full Text] [Related]
19. Whole Body Metabolic Tumor Volume and Total Lesion Glycolysis Predict Survival in Patients with Adrenocortical Carcinoma. Satoh K; Patel D; Dieckmann W; Nilubol N; Kebebew E Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S714-20. PubMed ID: 26282908 [TBL] [Abstract][Full Text] [Related]
20. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Chen HH; Chiu NT; Su WC; Guo HR; Lee BF Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]